EP2397155 - Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway [Right-click to bookmark this link] | |||
Former [2011/51] | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway | ||
[2017/28] | Status | Patent revoked Status updated on 08.03.2024 Database last updated on 24.08.2024 | |
Former | The patent has been granted Status updated on 10.11.2017 | ||
Former | Grant of patent is intended Status updated on 28.06.2017 | ||
Former | Examination is in progress Status updated on 01.11.2016 | Most recent event Tooltip | 08.03.2024 | Revocation of patent | published on 10.04.2024 [2024/15] | Applicant(s) | For all designated states Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215 / US | For all designated states The Brigham and Women's Hospital, Inc. 75 Francis Street Boston, MA 02115 / US | For all designated states Emory University 1599 Clifton Road NE 4th Floor Atlanta, GA 30322 / US | For all designated states President and Fellows of Harvard College 17 Quincy Street Cambridge, MA 02138 / US | [2017/28] |
Former [2013/45] | For all designated states Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215 / US | ||
For all designated states The Brigham and Women's Hospital, Inc. 1249 Boyleston street, Suite 201 Boston, Massachusetts 02215 / US | |||
For all designated states Emory University 201 Dowman Drive 101 Administration Bldg. Atlanta, GA 30322-1018 / US | |||
For all designated states President and Fellows of Harvard College 17 Quincy Street Cambridge, MA 02138 / US | |||
Former [2011/51] | For all designated states Dana Farber Cancer Institute 44 Binney Street - Jimmy Fund Building Boston, MA 02115 / US | ||
For all designated states The Brigham and Women's Hospital, Inc. 1249 Boyleston street, Suite 201 Boston, Massachusetts 02215 / US | |||
For all designated states Emory University 201 Dowman Drive 101 Administration Bldg. Atlanta, GA 30322-1018 / US | |||
For all designated states The President and Fellows of Harvard College 17 Quincy Street Cambridge MA 02138-3805 / US | Inventor(s) | 01 /
Freeman, Gordan 305 Walnut Street Brookline, MA 02445 / US | 02 /
Sharpe, Arlene 305 Walnut Street Brookline, MA 02445 / US | 03 /
Dorfman, David M. 42 Welland Road Brookline, MA 02445 / US | 04 /
Ahmed, Rafi 1811 Durand Mill Drive Atlanta, GA 30307 / US | 05 /
Barber, Daniel 5440 Marinelli Road, Apt. 206 North Bethesda, MD 20852 / US | 06 /
Wherry, E. John 110 Myrtie Avenue Havertown, Pennsylvania 19083 / US | [2011/51] | Representative(s) | Forresters IP LLP Skygarden Erika-Mann-Straße 11 80636 München / DE | [N/P] |
Former [2017/50] | Donald, Jenny Susan, et al Forresters IP LLP Skygarden Erika-Mann-Strasse 11 80636 München / DE | ||
Former [2012/13] | Gowshall, Jonathan Vallance, et al Forrester & Boehmert SkyGarden Erika-Mann-Strasse 11 80636 München / DE | ||
Former [2011/51] | Gowshall, Jonathan Vallance Forrester & Boehmert Pettenkoferstrasse 20-22 80336 München / DE | Application number, filing date | 11162667.7 | 08.06.2006 | [2011/51] | Priority number, date | US20050688872P | 08.06.2005 Original published format: US 688872 P | [2011/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2397155 | Date: | 21.12.2011 | Language: | EN | [2011/51] | Type: | B1 Patent specification | No.: | EP2397155 | Date: | 13.12.2017 | Language: | EN | [2017/50] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 18.11.2011 | Classification | IPC: | A61K39/00, A61P31/12, A61P31/18, A61P31/22, G01N33/53, // C07K16/28 | [2017/28] | CPC: |
A61K31/713 (EP,IL,US);
C07K16/2803 (IL,US);
A61K39/395 (KR,RU);
A61K38/1709 (EP,IL,US);
A61K39/39 (EP,IL,US);
A61K39/3955 (US);
A61K39/39558 (US);
A61K45/06 (EP,IL,US);
A61P1/16 (EP);
A61P31/00 (EP);
A61P31/04 (EP);
A61P31/06 (EP);
A61P31/10 (EP);
A61P31/12 (EP);
A61P31/14 (EP);
A61P31/18 (EP);
A61P31/20 (EP);
A61P31/22 (EP);
A61P33/00 (EP);
A61P33/02 (EP);
A61P33/06 (EP);
A61P35/00 (EP,RU);
A61P37/04 (EP);
A61P43/00 (EP);
C07K16/28 (KR);
C07K16/2818 (EP,IL,US);
C07K16/2827 (EP,IL,US);
C12N15/1138 (US);
G01N33/5011 (EP,IL,US);
G01N33/505 (EP,IL,US);
G01N33/53 (KR);
G01N33/57484 (EP,IL,US);
G01N33/57492 (EP,IL,US);
A61K2039/505 (EP,IL,US);
A61K2039/507 (US);
A61K2039/55516 (EP,IL,US);
A61K2039/55566 (EP,IL,US);
A61K2039/572 (EP,IL,US);
C07K2317/70 (EP,IL,US);
C07K2317/73 (US);
C07K2317/74 (EP,IL,US);
C07K2317/76 (EP,IL,US);
|
Former IPC [2011/51] | A61K39/395, G01N33/53, // C07K16/28 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2017/50] |
Former [2011/51] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | Title | German: | Verfahren und Zusammensetzungen zur Behandlung persistenter Infektionen mittels Hemmung des programmierten 1 (PD-1)-Zelltodweges | [2017/28] | English: | Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway | [2017/28] | French: | Procédés et compositions pour le traitement d'infections persistantes en inhibant la voie de la mort cellulaire programmée (PD-1) | [2017/28] |
Former [2011/51] | Verfahren und Zusammensetzungen zur Behandlung persistenter Infektionen und Krebs mittels Hemmung des programmierten 1 (pd-1)-Zelltodweges | ||
Former [2011/51] | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway | ||
Former [2011/51] | Procédés et compositions pour le traitement du cancer et d'infections persistantes en inhibant la voie de la mort cellulaire programmée (pd-1) | Examination procedure | 21.06.2012 | Amendment by applicant (claims and/or description) | 21.06.2012 | Examination requested [2012/31] | 06.03.2013 | Despatch of a communication from the examining division (Time limit: M06) | 30.08.2013 | Reply to a communication from the examining division | 06.09.2013 | Observations by third parties | 16.09.2013 | Despatch of a communication from the examining division (Time limit: M02) | 26.09.2013 | Reply to a communication from the examining division | 07.11.2014 | Despatch of a communication from the examining division (Time limit: M04) | 11.03.2015 | Reply to a communication from the examining division | 22.06.2015 | Despatch of a communication from the examining division (Time limit: M04) | 22.10.2015 | Reply to a communication from the examining division | 11.03.2016 | Despatch of a communication from the examining division (Time limit: M04) | 15.07.2016 | Reply to a communication from the examining division | 21.10.2016 | Despatch of a communication from the examining division (Time limit: M04) | 23.01.2017 | Reply to a communication from the examining division | 05.07.2017 | Communication of intention to grant the patent | 01.11.2017 | Fee for grant paid | 01.11.2017 | Fee for publishing/printing paid | 01.11.2017 | Receipt of the translation of the claim(s) | 22.11.2017 | Request for correction of the decision to grant filed | Parent application(s) Tooltip | EP06784684.0 / EP1907000 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060784684) is 15.04.2009 | Opposition(s) | Opponent(s) | 01
11.09.2018
14.09.2018
ADMISSIBLE Sanofi 54 Rue La Boétie 75008 Paris / FR Opponent's representative Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | 02
12.09.2018
17.09.2018
ADMISSIBLE Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591 / US Opponent's representative J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | 03
13.09.2018
18.09.2018
ADMISSIBLE Janssen Sciences Ireland UC Eastgate Village Eastgate Little Island Cork / IE Opponent's representative Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [N/P] |
Former [2021/37] | |||
Opponent(s) | 01
11.09.2018
14.09.2018
ADMISSIBLE Sanofi 54 Rue La Boétie 75008 Paris / FR Opponent's representative Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
02
12.09.2018
17.09.2018
ADMISSIBLE Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591 / US Opponent's representative J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB | |||
03
13.09.2018
18.09.2018
ADMISSIBLE Janssen Sciences Ireland UC Eastgate Village Eastgate Little Island Cork / IE Opponent's representative Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | |||
Former [2018/43] | |||
Opponent(s) | 01
11.09.2018
14.09.2018
ADMISSIBLE Sanofi 54 Rue La Boétie 75008 Paris / FR Opponent's representative Holland, David Christopher Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
02
12.09.2018
17.09.2018
ADMISSIBLE Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591 / US Opponent's representative J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | |||
03
13.09.2018
18.09.2018
ADMISSIBLE Janssen Sciences Ireland UC Eastgate Village Eastgate Little Island Cork / IE Opponent's representative Wise, Daniel Joseph Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | |||
Former [2018/42] | |||
Opponent(s) | 01
11.09.2018
ADMISSIBLE Sanofi 54 Rue La Boétie 75008 Paris / FR Opponent's representative Holland, David Christopher Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
02
12.09.2018
ADMISSIBLE Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591 / US Opponent's representative J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | 27.09.2018 | Invitation to proprietor to file observations on the notice of opposition | 07.02.2019 | Reply of patent proprietor to notice(s) of opposition | 09.12.2019 | Date of oral proceedings | 20.01.2020 | Despatch of minutes of oral proceedings | 20.01.2020 | Despatch of communication that the patent will be revoked | 18.10.2023 | Legal effect of revocation of patent [2024/15] | Appeal following opposition | 19.03.2020 | Appeal received No. T0737/20 | 02.06.2020 | Statement of grounds filed | 18.10.2023 | Result of appeal procedure: appeal of the proprietor was rejected | 07.03.2024 | Despatch of the decision of the Board of Appeal | 18.10.2023 | Date of oral proceedings | Fees paid | Renewal fee | 15.04.2011 | Renewal fee patent year 03 | 15.04.2011 | Renewal fee patent year 04 | 18.04.2011 | Renewal fee patent year 05 | 13.06.2011 | Renewal fee patent year 06 | 14.06.2012 | Renewal fee patent year 07 | 10.06.2013 | Renewal fee patent year 08 | 31.03.2014 | Renewal fee patent year 09 | 10.06.2015 | Renewal fee patent year 10 | 10.06.2016 | Renewal fee patent year 11 | 16.06.2017 | Renewal fee patent year 12 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 08.06.2006 | AT | 13.12.2017 | CY | 13.12.2017 | CZ | 13.12.2017 | DK | 13.12.2017 | EE | 13.12.2017 | ES | 13.12.2017 | FI | 13.12.2017 | IT | 13.12.2017 | LT | 13.12.2017 | LV | 13.12.2017 | MC | 13.12.2017 | NL | 13.12.2017 | PL | 13.12.2017 | PT | 13.12.2017 | RO | 13.12.2017 | SE | 13.12.2017 | SI | 13.12.2017 | SK | 13.12.2017 | TR | 13.12.2017 | BG | 13.03.2018 | GR | 14.03.2018 | IS | 13.04.2018 | IE | 08.06.2018 | LU | 08.06.2018 | BE | 30.06.2018 | [2020/27] |
Former [2020/16] | AT | 13.12.2017 | |
CY | 13.12.2017 | ||
CZ | 13.12.2017 | ||
DK | 13.12.2017 | ||
EE | 13.12.2017 | ||
ES | 13.12.2017 | ||
FI | 13.12.2017 | ||
IT | 13.12.2017 | ||
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
MC | 13.12.2017 | ||
NL | 13.12.2017 | ||
PL | 13.12.2017 | ||
RO | 13.12.2017 | ||
SE | 13.12.2017 | ||
SI | 13.12.2017 | ||
SK | 13.12.2017 | ||
TR | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
IS | 13.04.2018 | ||
IE | 08.06.2018 | ||
LU | 08.06.2018 | ||
BE | 30.06.2018 | ||
Former [2019/24] | AT | 13.12.2017 | |
CY | 13.12.2017 | ||
CZ | 13.12.2017 | ||
DK | 13.12.2017 | ||
EE | 13.12.2017 | ||
ES | 13.12.2017 | ||
FI | 13.12.2017 | ||
IT | 13.12.2017 | ||
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
MC | 13.12.2017 | ||
NL | 13.12.2017 | ||
PL | 13.12.2017 | ||
RO | 13.12.2017 | ||
SE | 13.12.2017 | ||
SI | 13.12.2017 | ||
SK | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
IS | 13.04.2018 | ||
IE | 08.06.2018 | ||
LU | 08.06.2018 | ||
BE | 30.06.2018 | ||
Former [2019/19] | AT | 13.12.2017 | |
CY | 13.12.2017 | ||
CZ | 13.12.2017 | ||
DK | 13.12.2017 | ||
EE | 13.12.2017 | ||
ES | 13.12.2017 | ||
FI | 13.12.2017 | ||
IT | 13.12.2017 | ||
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
MC | 13.12.2017 | ||
NL | 13.12.2017 | ||
PL | 13.12.2017 | ||
RO | 13.12.2017 | ||
SE | 13.12.2017 | ||
SI | 13.12.2017 | ||
SK | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
IS | 13.04.2018 | ||
IE | 08.06.2018 | ||
LU | 08.06.2018 | ||
Former [2019/17] | AT | 13.12.2017 | |
CY | 13.12.2017 | ||
CZ | 13.12.2017 | ||
DK | 13.12.2017 | ||
EE | 13.12.2017 | ||
ES | 13.12.2017 | ||
FI | 13.12.2017 | ||
IT | 13.12.2017 | ||
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
MC | 13.12.2017 | ||
NL | 13.12.2017 | ||
PL | 13.12.2017 | ||
RO | 13.12.2017 | ||
SE | 13.12.2017 | ||
SI | 13.12.2017 | ||
SK | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
IS | 13.04.2018 | ||
LU | 08.06.2018 | ||
Former [2019/15] | AT | 13.12.2017 | |
CY | 13.12.2017 | ||
CZ | 13.12.2017 | ||
DK | 13.12.2017 | ||
EE | 13.12.2017 | ||
ES | 13.12.2017 | ||
FI | 13.12.2017 | ||
IT | 13.12.2017 | ||
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
MC | 13.12.2017 | ||
NL | 13.12.2017 | ||
PL | 13.12.2017 | ||
RO | 13.12.2017 | ||
SE | 13.12.2017 | ||
SI | 13.12.2017 | ||
SK | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
IS | 13.04.2018 | ||
Former [2019/13] | AT | 13.12.2017 | |
CY | 13.12.2017 | ||
CZ | 13.12.2017 | ||
DK | 13.12.2017 | ||
EE | 13.12.2017 | ||
ES | 13.12.2017 | ||
FI | 13.12.2017 | ||
IT | 13.12.2017 | ||
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
NL | 13.12.2017 | ||
PL | 13.12.2017 | ||
RO | 13.12.2017 | ||
SE | 13.12.2017 | ||
SI | 13.12.2017 | ||
SK | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
IS | 13.04.2018 | ||
Former [2018/51] | AT | 13.12.2017 | |
CY | 13.12.2017 | ||
CZ | 13.12.2017 | ||
DK | 13.12.2017 | ||
EE | 13.12.2017 | ||
ES | 13.12.2017 | ||
FI | 13.12.2017 | ||
IT | 13.12.2017 | ||
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
NL | 13.12.2017 | ||
PL | 13.12.2017 | ||
RO | 13.12.2017 | ||
SE | 13.12.2017 | ||
SK | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
IS | 13.04.2018 | ||
Former [2018/40] | AT | 13.12.2017 | |
CY | 13.12.2017 | ||
CZ | 13.12.2017 | ||
EE | 13.12.2017 | ||
ES | 13.12.2017 | ||
FI | 13.12.2017 | ||
IT | 13.12.2017 | ||
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
NL | 13.12.2017 | ||
PL | 13.12.2017 | ||
RO | 13.12.2017 | ||
SE | 13.12.2017 | ||
SK | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
IS | 13.04.2018 | ||
Former [2018/39] | AT | 13.12.2017 | |
CY | 13.12.2017 | ||
CZ | 13.12.2017 | ||
EE | 13.12.2017 | ||
ES | 13.12.2017 | ||
FI | 13.12.2017 | ||
IT | 13.12.2017 | ||
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
NL | 13.12.2017 | ||
PL | 13.12.2017 | ||
SE | 13.12.2017 | ||
SK | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
IS | 13.04.2018 | ||
Former [2018/38] | AT | 13.12.2017 | |
CY | 13.12.2017 | ||
CZ | 13.12.2017 | ||
EE | 13.12.2017 | ||
ES | 13.12.2017 | ||
FI | 13.12.2017 | ||
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
NL | 13.12.2017 | ||
PL | 13.12.2017 | ||
SE | 13.12.2017 | ||
SK | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
IS | 13.04.2018 | ||
Former [2018/37] | CY | 13.12.2017 | |
CZ | 13.12.2017 | ||
EE | 13.12.2017 | ||
ES | 13.12.2017 | ||
FI | 13.12.2017 | ||
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
NL | 13.12.2017 | ||
PL | 13.12.2017 | ||
SE | 13.12.2017 | ||
SK | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
Former [2018/34] | FI | 13.12.2017 | |
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
NL | 13.12.2017 | ||
SE | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
Former [2018/24] | FI | 13.12.2017 | |
LT | 13.12.2017 | ||
LV | 13.12.2017 | ||
SE | 13.12.2017 | ||
BG | 13.03.2018 | ||
GR | 14.03.2018 | ||
Former [2018/23] | FI | 13.12.2017 | |
LT | 13.12.2017 | ||
SE | 13.12.2017 | ||
GR | 14.03.2018 | ||
Former [2018/22] | FI | 13.12.2017 | |
LT | 13.12.2017 | Documents cited: | Search | [A]WO0200730 (GENETICS INST [US], et al) [A] 1 * page 107 *; | [XY]WO2004004771 (ONO PHARMACEUTICAL CO [JP], et al) [X] 1,4-8,10-17 * the whole document * [Y] 2,3; | [A]WO2004056875 (WYETH CORP [US], et al) [A] 1 * paragraph [0042] *; | EP1537878 [ ] (ONO PHARMACEUTICAL CO [JP], et al) [ ] * paragraph [0035] * * paragraph [0037] * * paragraph [0055] * * paragraph [0057] * * paragraph [0051] *; | [Y] - TRABATTONI DARIA ET AL, "B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression.", BLOOD 1 APR 2003, (20030401), vol. 101, no. 7, ISSN 0006-4971, pages 2514 - 2520, XP002419628 [Y] 2,3 * page 2516 * DOI: http://dx.doi.org/10.1182/blood-2002-10-3065 | [X] - HIRANO FUMIYA ET AL, "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.", CANCER RESEARCH 1 FEB 2005, (20050201), vol. 65, no. 3, ISSN 0008-5472, pages 1089 - 1096, XP002419626 [X] 1 * page 1091, column R * | [A] - IWAI YOSHIKO ET AL, "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, (20020917), vol. 99, no. 19, ISSN 0027-8424, pages 12293 - 12297, XP002398159 [A] 1 * page 12295 * DOI: http://dx.doi.org/10.1073/pnas.192461099 | [AP] - BARBER DANIEL L ET AL, "Restoring function in exhausted CD8 T cells during chronic viral infection.", NATURE 9 FEB 2006, (20060209), vol. 439, no. 7077, ISSN 1476-4687, pages 682 - 687, XP002419629 [AP] 1-17 * the whole document * DOI: http://dx.doi.org/10.1038/nature04444 | [AP] - HE LANXIANG ET AL, "Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma.", ANTICANCER RESEARCH 2005 SEP-OCT, (200509), vol. 25, no. 5, ISSN 0250-7005, pages 3309 - 3313, XP009078741 [AP] 1 * abstract * | [A] - BLANK CHRISTIAN ET AL, "Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII APR 2005, (200504), vol. 54, no. 4, ISSN 0340-7004, pages 307 - 314, XP002419627 [A] 1 * figure 2 * DOI: http://dx.doi.org/10.1007/s00262-004-0593-x | [A] - OHIGASHI YUICHIRO ET AL, "Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 APR 2005, (20050415), vol. 11, no. 8, ISSN 1078-0432, pages 2947 - 2953, XP002419631 [A] 1 * the whole document * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-04-1469 | by applicant | US3625214 | US4230767 | US4233402 | US4275149 | US4376110 | US4659678 | US4727022 | US4789734 | WO8907136 | US4925673 | US5698520 | US5954687 | US6368832 | US2002107363 | US2002106730 | US2002110836 | US2002160000 | US2002164600 | US2003039653 | US2003044768 | US2003064380 | US6579854 | US2003166531 | US2003232323 | US2004137577 | US6808710 | - ISHIDA ET AL., EMBO J., (1992), vol. 11, pages 3887 - 3895 | - SHINOHARA ET AL., GENOMICS, (1994), vol. 23, pages 704 - 706 | - KANG ET AL., SCIENCE, (1992), vol. 257, page 1134 | - BERZOFSKY ET AL., J. CLIN. INVEST., (2004), vol. 114, pages 456 - 462 | - JOLIOT ET AL., PROC NATL ACAD SCI USA, (1991), vol. 88, pages 1864 - 1868 | - ROSENBERG ET AL., N. ENG. J. MED., (1990), vol. 323, no. 9, pages 570 - 578 | - KOTIN ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 2211 - 2215 | - LU ET AL., Abstracts of the Meeting on Gene Therapy, COLD SPRING HARBOR LABORATORY, page 66 | - GREGORIADIS, Drug Carriers in Biology and Medicine, ACADEMIC PRESS, (1979), pages 287 - 341 | - DONG ET AL., NATURE, (1999), vol. 5, pages 1365 - 1369 | - O'MARCAIGH AS, JACOBSON RM, "Estimating The Predictive Value Of A Diagnostic Test, How To Prevent Misleading Or Confusing Results", CLIN. PED., (1993), vol. 32, no. 8, pages 485 - 491 | - "Clinical Interpretation Of Laboratory Procedures", SHULTZ, Fundamentals of Clinical Chemistry, W.B. SAUNDERS COMPANY, (1996), pages 192 - 199 | - ZWEIG ET AL., "ROC Curve Analysis: An Example Showing The Relationships Among Serum Lipid And Apolipoprotein Concentrations In Identifying Patients With Coronory Artery Disease", CLIN. CHEM., (1992), vol. 38, no. 8, pages 1425 - 1428 | - KAECH ET AL., CELL, (2002), vol. 111, pages 837 - 51 | - AHMED ET AL., J. VIROL., (1984), vol. 51, pages 34 - 41 | - WHERRY ET AL., J. VIROL., (2003), vol. 77, pages 4911 - 27 | other | WO2004004771 | Opposition | WO0114557 | WO0200730 | WO02079499 | WO02086083 | WO2004004771 | WO2007005874 | US2007122378 | - IWAI et al., "PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver", J. Exp. Med., (20030000), vol. 198, no. 1, pages 39 - 50, XP055011230 DOI: http://dx.doi.org/10.1084/jem.20022235 | - TRABATTONI et al., "B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression", Blood, (20030000), vol. 101, no. 7, pages 2514 - 20, XP002419628 DOI: http://dx.doi.org/10.1182/blood-2002-10-3065 | - BARBER et al., "Restoring function in exhausted CD8 T cells during chronic viral infection", Nature, (20060000), vol. 439, no. 7077, pages 682 - 687, XP002419629 DOI: http://dx.doi.org/10.1038/nature04444 | - ISOGAWA et al., "Oscillating CDS+ T Cell Effector Functions after Antigen Recognition in the Liver", Immunity, (20050000), vol. 23, no. 1, pages 53 - 63, XP055519557 | - KIRCHBERGER et al., "Human Rhinoviruses Inhibit the Accessory Function of Dendritic Cells by Inducing Sialoadhesin and B7-Hl Expression1", J. Immunol., (20050000), vol. 175, no. 2, pages 1145 - 1152, XP055519558 | - OKAZAKI et al., "The PD-1-PD-L pathway in immunological tolerance", Trends in Immunology, (20060000), vol. 27, no. 4, pages 195 - 201, XP005365361 DOI: http://dx.doi.org/10.1016/j.it.2006.02.001 | - CARUNTU et al., "CccDNA Persistence during Natural Evolution of Chronic VHB Infection", Romanian J. Gastroenterology, (20051200), vol. 14, no. 4, pages 373 - 377, XP055519560 | - JEON et al., "PD-L1/B-7-H1 regulates the survival but not the function of CD8+ T cells in HSV-1 latently infected trigeminal ganglia", J. Immunol., (20130000), vol. 190, no. 12, pages 6277 - 6286, XP055519561 DOI: http://dx.doi.org/10.4049/jimmunol.1300582 | - NAKAMOTO et al., "Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmentalization", Gastroenterology, (20080000), vol. 134, no. 7, pages 1927 - 1937, XP022694434 DOI: http://dx.doi.org/10.1053/j.gastro.2008.02.033 |